ForPatients
by Roche

Huntington Disease (HD)

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

Trial Status	Trial Runs In	Trial Identifier
Completed	17 Countries	NCT03761849 2018-002987-14 BN40423

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy, safety, and biomarker effects of RO7234292 (RG6042) compared with placebo in participants with manifest Huntington's disease (HD)

Hoffmann-La Roche Sponsor	**Phase 3** Phase

NCT03761849 2018-002987-14 BN40423
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=25 Years & <= 65 Years	No

© 2022 F. Hoffmann-La Roche Ltd